Novartis CEO plays down prospects for Actelion bid: Blick

VIENNA (Reuters) - Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction.

Novartis CEO plays down prospects for Actelion bid: Blick
Read More


Bagikan Berita Ini